Integrated Biopharma Stock

Integrated Biopharma P/E

The (Price Earnings Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the earnings per share. The P/E indicates how many years it would take to recoup the current share price through the expected earnings per share. A low P/E may indicate that a stock is undervalued, while a high P/E may suggest an overvalued stock. However, the P/E alone should not be considered the sole basis for an investment decision, as other factors must also be taken into account. of Integrated Biopharma (INBP) as of Aug 12, 2026 is 11.52. In the previous year, (Price Earnings Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the earnings per share. The P/E indicates how many years it would take to recoup the current share price through the expected earnings per share. A low P/E may indicate that a stock is undervalued, while a high P/E may suggest an overvalued stock. However, the P/E alone should not be considered the sole basis for an investment decision, as other factors must also be taken into account. was 83.11 — a change of -86.14% (lower).

P/E

11.52

YoY

-86.14%

Last updated:

As of Aug 12, 2026, Integrated Biopharma's P/E ratio was 11.52, a -86.14% change from the 83.11 P/E ratio recorded in the previous year.

The Integrated Biopharma P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/E
Date
P/E
Jan 1, 2018
0.00 base
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
0.00 base
Jan 1, 2022
0.00 base
Jan 1, 2023
0.00 base
Jan 1, 2024
0.00 base
Jan 1, 2025
0.00 base
YEARP/E
2025 -
2024 -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
2007 -
2006 -
Access this data via the Eulerpool API
Get Free API Key

Integrated Biopharma Stock analysis

What does Integrated Biopharma do? Integrated Biopharma Inc. is a New York-based company specializing in the development, manufacturing, and marketing of health products. Founded in 1979, the company has acquired extensive experience in the industry. Integrated Biopharma's business activities encompass four main areas: biopharmaceuticals, pharmaceuticals, dietary supplements, and veterinary products. Each of these divisions is focused on the development and manufacturing of specific products, contributing to the overall business of the company. In the biopharmaceuticals sector, the company focuses on developing therapeutic products for rare and severe diseases. The product development is carried out in close collaboration with the Columbia University Medical School. In the pharmaceuticals sector, Integrated Biopharma produces generics as well as its own products targeting the treatment of diabetes, cancer, and cardiovascular diseases, among others. Dietary supplements are also part of Integrated Biopharma's product portfolio, with a focus on manufacturing vitamin and mineral supplements, as well as herbal dietary supplements. Additionally, the company offers a variety of veterinary products, including preparations for the health of domestic and farm animals, as well as medications for the treatment of animal diseases. One important business model of Integrated Biopharma is the manufacturing and marketing of mostly patent-free, yet high-quality products. Furthermore, the company collaborates closely with other companies and institutions to develop new products and technologies. Another important strategy of Integrated Biopharma is to market its products worldwide. The company has distribution partners in many countries, including China, Canada, Mexico, France, and Germany. Integrated Biopharma places a strong emphasis on the highest quality standards and therefore invests in modern infrastructure and a well-trained workforce. The company operates its own production facilities and research institutions in the USA and China. Among Integrated Biopharma's most well-known products are the diabetes medication "GlipiZIDE," the carcinoma medication "Paclitaxel," and the veterinary antibiotic "Gentamicin Sulfate." Overall, Integrated Biopharma has received numerous awards and certifications for its products and business activities in recent years. The high quality and effectiveness of its preparations, as well as its responsible approach to resources and the environment, make Integrated Biopharma an important player in the healthcare industry. Integrated Biopharma is one of the most popular companies on Eulerpool.

P/E Details

Deciphering Integrated Biopharma's P/E Ratio

The Price to Earnings (P/E) Ratio of Integrated Biopharma is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Integrated Biopharma's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Integrated Biopharma is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Integrated Biopharma’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Integrated Biopharma stock

(Price Earnings Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the earnings per share. The P/E indicates how many years it would take to recoup the current share price through the expected earnings per share. A low P/E may indicate that a stock is undervalued, while a high P/E may suggest an overvalued stock. However, the P/E alone should not be considered the sole basis for an investment decision, as other factors must also be taken into account. of Integrated Biopharma is 11.52 in 2026.

(Price Earnings Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the earnings per share. The P/E indicates how many years it would take to recoup the current share price through the expected earnings per share. A low P/E may indicate that a stock is undervalued, while a high P/E may suggest an overvalued stock. However, the P/E alone should not be considered the sole basis for an investment decision, as other factors must also be taken into account. of Integrated Biopharma changed from 83.11 to 11.52, representing a -86.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of (Price Earnings Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the earnings per share. The P/E indicates how many years it would take to recoup the current share price through the expected earnings per share. A low P/E may indicate that a stock is undervalued, while a high P/E may suggest an overvalued stock. However, the P/E alone should not be considered the sole basis for an investment decision, as other factors must also be taken into account. Integrated Biopharma since 2006 – with annual values, charts, and detailed analysis.

The price-earnings ratio (P/E ratio) is a key figure for evaluating a stock. The stock price is compared to the earnings per share. The ratio therefore expresses the number of years it takes for a company to generate the current earnings to match the stock price.

P/E ratio formula:
P/E ratio = Stock price / Earnings per Share (EPS)
If the earnings per share (EPS) is not readily available, it can be calculated by dividing the company's total earnings by the number of shares issued.

EPS formula:
Total earnings of the company / Number of shares issued
The earnings per share (EPS) can usually be easily found on most financial websites.

The P/E ratio is one of the most commonly used indicators for valuing stocks. However, the correct application of the P/E ratio is slightly more complicated than the formula described above would suggest. Therefore, it is always only a snapshot and not a reliable consideration of the future. If future earnings were to increase without any change in the stock price, the P/E ratio would accordingly decrease.

To evaluate (Price Earnings Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the earnings per share. The P/E indicates how many years it would take to recoup the current share price through the expected earnings per share. A low P/E may indicate that a stock is undervalued, while a high P/E may suggest an overvalued stock. However, the P/E alone should not be considered the sole basis for an investment decision, as other factors must also be taken into account.'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for (Price Earnings Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the earnings per share. The P/E indicates how many years it would take to recoup the current share price through the expected earnings per share. A low P/E may indicate that a stock is undervalued, while a high P/E may suggest an overvalued stock. However, the P/E alone should not be considered the sole basis for an investment decision, as other factors must also be taken into account..

A 'good' varies by industry and company stage. On Eulerpool, you can compare (Price Earnings Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the earnings per share. The P/E indicates how many years it would take to recoup the current share price through the expected earnings per share. A low P/E may indicate that a stock is undervalued, while a high P/E may suggest an overvalued stock. However, the P/E alone should not be considered the sole basis for an investment decision, as other factors must also be taken into account.'s Integrated Biopharma with sector peers and the industry average to assess whether it is attractive.

The P/E ratio in evaluating a stock.

The price-earnings ratio (P/E ratio) is an important financial ratio that is often used by investors to assess the attractiveness of a stock. It is an indicator of a company's earnings and valuation, and provides an indication of whether a stock is overvalued or undervalued. It is also used as an indicator of whether a stock is "expensive" or "cheap".

History of P/E ratio

The P/E ratio was first used in 1881 by the famous financial scientist Benjamin Graham. He developed the P/E ratio as a means to evaluate whether a stock is trading at a "good" or "bad" price. Since then, the P/E ratio has had a long history in the financial world, particularly among investors who are looking for a way to evaluate stocks in an informed manner.

Calculation of the P/E ratio

The P/E ratio is calculated by dividing the current stock price by the earnings per share. A simple formula for calculating the P/E ratio is as follows:

P/E ratio = Stock price / Earnings per share

Example: If a stock is traded at the current price of $10 and the earnings per share is $1, the P/E ratio would be 10 ($10 / $1 = 10).

Application of the P/E ratio

Investors use the P/E ratio to assess the attractiveness of a stock. A high P/E ratio can indicate that a stock is overvalued, while a low P/E ratio means that a stock is undervalued. Investors can then decide whether to buy, sell, or hold a stock based on this information. Another reason why investors use the P/E ratio is to check how stocks perform compared to other stocks or the market as a whole. If a stock's P/E ratio is higher than the overall market's P/E ratio, this may mean that the stock is overvalued, and investors can decide whether to sell or hold the stock. Investors usually also use the P/E ratio to compare stocks over time. If a stock has a P/E ratio of 10 and a year later has a P/E ratio of 20, this may mean that the stock is overvalued. Investors can then decide whether to hold or sell the stock.

Advantages and Disadvantages of using the P/E ratio

BenefitsThe P/E ratio is a useful tool to assess the attractiveness of a stock and to evaluate how a stock is performing compared to the market. It is a simple tool that can assist investors in deciding whether to buy, sell, or hold a stock.

DisadvantagesThe P/E ratio is a simple tool that does not provide any information about the future performance of a stock. It can be difficult to predict the future performance of a stock, and sometimes the P/E ratio can give a false picture of a stock. Therefore, investors must be cautious when relying on the P/E ratio.

In addition, the P/E ratio can vary depending on the industry, which makes comparability difficult. For example, a stock in a certain industry may have a low P/E ratio, while another stock in a different industry may have a higher P/E ratio. Therefore, investors must be cautious when relying on the P/E ratio.

Conclusion

The P/E ratio is a useful tool that can assist investors in assessing the attractiveness and value of a stock. It can also be used to check how a stock is performing in comparison to the market. However, it is important to note that it is a simple tool that does not make any statement about the future performance of a stock, and investors must be cautious when relying on the P/E ratio.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Integrated Biopharma

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Integrated Biopharma